B. Riley Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

B. Riley Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-8,089	Closed	-$367K	–	661
2017 Q3	$367K	Buy	+8,089	New	+$323K	0.06%	330
2016 Q4	–	Sell	-3,910	Closed	-$241K	–	635
2016 Q3	$241K	Buy	+3,910	New	+$118K	0.05%	476
2015 Q1	–	Sell	-28,040	Closed	-$2.24K	–	1793
2014 Q4	$2.24K	Buy	28,040 +11,720	+72%	+$198K	0.05%	522
2014 Q3	$363K	Sell	16,320 -18,680	-53%	-$422K	0.09%	289
2014 Q2	$522K	Buy	35,000 +27,000	+338%	+$853K	0.12%	191
2014 Q1	$192K	Hold	8,000	–	–	0.06%	402
2013 Q4	$163K	Buy	+8,000	New	+$238K	0.05%	406
2013 Q3	–	Sell	-2,375	Closed	-$90K	–	738
2013 Q2	$90K	Buy	+2,375	New	+$84.9K	0.03%	572

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

B. Riley Wealth Advisors's SRPT Position: Q4 2017 in Review

B. Riley Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2017, closing a stake of 8,089 shares — an estimated $367K sold.

B. Riley Wealth Advisors first reported a position in SRPT in Q2 2013 and held it in 8 quarters. The position peaked at $522K in Q2 2014. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

B. Riley Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q4 2017 after selling out during the quarter.
B. Riley Wealth Advisors sold 8,089 Sarepta Therapeutics shares in Q4 2017, an estimated $367K.
B. Riley Wealth Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 8 quarters.
B. Riley Wealth Advisors's Sarepta Therapeutics position peaked at $522K in Q2 2014.
254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2017, filed 15 Feb 2018.